Patents by Inventor Boyoung Kim

Boyoung Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11171423
    Abstract: In a meta-structure having multifunctional properties according to an exemplary embodiment of the present invention, a plurality of unit blocks controlling a property of a wave is combined on a plane or in a space in a predetermined pattern to form one structure, at least one of the plurality of unit blocks is formed to have a different size, and a frequency range of a wave controlled is changed according to the size of the unit block.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: November 9, 2021
    Assignees: KOREA INSTITUTE OF MACHINERY & MATERIALS, CENTER FOR ADVANCED META-MATERIALS
    Inventors: Boyoung Kang, Hak Joo Lee, Duckjong Kim, Jae-Hyun Kim
  • Patent number: 11114036
    Abstract: A scan driver includes a plurality of circuit stages, each circuit stage including a first input part configured to transfer a carry signal to a first node in response to a first clock signal, a second input part configured to transfer the first clock signal to a second node in response to a signal of the first node, a first output part configured to transfer a third clock signal to an output terminal in response to a signal of the second node, a holding part configured to maintain a signal of a third node response to a second clock signal, and a second output part configured to transfer a signal of the third node to the output terminal in response to the second clock signal.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: September 7, 2021
    Assignee: Samsung Display Co., Ltd.
    Inventors: Boyoung Chung, Youngwan Seo, Dongwoo Kim, Yeonkyung Kim, Chong Chul Chai
  • Patent number: 11037477
    Abstract: Provided are a display apparatus, and a method and system for controlling the same, the display apparatus including: a display; an interface; a storage; and a processor configured to transmit information on a refresh rate of the display, stored in the storage, to a source apparatus connected to the interface; based on an image signal received from the source apparatus being displayed as an image on the display at a preset first refresh rate for more than a predetermined period, switch the refresh rate, stored in the storage, to a second refresh rate that is lower than the first refresh rate; transmit information about the second refresh rate to the source apparatus; and display the image on the display at the second refresh rate of the image signal received from the source apparatus.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: June 15, 2021
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyunmook Choi, Boyoung Kim, Hwichul Kim, Euihyung Yoo, Kwansoo Lee, Sanghyeok Lee
  • Publication number: 20210062199
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Application
    Filed: September 16, 2020
    Publication date: March 4, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Natalie PURSELL, Cheng LAI, Weimin WANG, Rachel STORR, Naim NAZEF, Boyoung KIM
  • Publication number: 20200283775
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Application
    Filed: October 12, 2018
    Publication date: September 10, 2020
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Natalie PURSELL, Cheng LAI, Weimin WANG, Rachel STORR, Naim NAZEF, Boyoung KIM
  • Publication number: 20200209206
    Abstract: A method of manufacturing a gas sensor for detecting xylene is provided. A method of manufacturing a gas sensor includes reacting a mixed material including a first material containing a cobalt (Co) element and a second material containing a chromium (Cr) element to form a CoCr2O4 hollow structure having a hollow shape.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 2, 2020
    Applicant: Korea University Research and Business Foundation
    Inventors: Jongheun LEE, Boyoung KIM, Jiwook YOON, Kunho LEE
  • Publication number: 20200105177
    Abstract: Provided are a display apparatus, and a method and system for controlling the same, the display apparatus including: a display; an interface; a storage; and a processor configured to transmit information on a refresh rate of the display, stored in the storage, to a source apparatus connected to the interface; based on an image signal received from the source apparatus being displayed as an image on the display at a preset first refresh rate for more than a predetermined period, switch the refresh rate, stored in the storage, to a second refresh rate that is lower than the first refresh rate; transmit information about the second refresh rate to the source apparatus; and display the image on the display at the second refresh rate of the image signal received from the source apparatus.
    Type: Application
    Filed: September 16, 2019
    Publication date: April 2, 2020
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyunmook Choi, Boyoung Kim, Hwichul Kim, Euihyung Yoo, Kwansoo Lee, Sanghyeok Lee
  • Patent number: 10532068
    Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: January 14, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
  • Patent number: 10239957
    Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Publication number: 20190015442
    Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurance of P is independently selected from Table 2; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
    Type: Application
    Filed: May 8, 2018
    Publication date: January 17, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
  • Patent number: 10010562
    Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: July 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
  • Publication number: 20170189441
    Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
    Type: Application
    Filed: November 3, 2014
    Publication date: July 6, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Publication number: 20170081425
    Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
    Type: Application
    Filed: November 3, 2014
    Publication date: March 23, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Patent number: 9233977
    Abstract: Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO2—, —O— or NRac—, wherein Rac is H, or C1-20 alkyl and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: January 12, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John A. McCauley, Hemaka A. Rajapakse, Thomas J. Greshock, John Sanders, Boyoung Kim, Vanessa L. Rada, Jonathan T. Kern, Heather H. Stevenson, Mark T. Bilodeau
  • Publication number: 20130296317
    Abstract: Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO2—, —O— or NRac—, wherein Rac is H, or C1-20 alkyl and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.
    Type: Application
    Filed: October 25, 2011
    Publication date: November 7, 2013
    Inventors: John A. McCauley, Hemaka A. Rajapakse, Thomas J. Greshock, John Sanders, Boyoung Kim, Vanessa L. Rada, Jonathan T. Kern, Heather H. Stevenson, Mark T. Bilodeau
  • Publication number: 20120022045
    Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X1, X2, ?3, Y, Z, R1, R2 and R3 are defined herein. The N compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: January 25, 2010
    Publication date: January 26, 2012
    Inventors: Shankar Venkatraman, John S. Wai, Wayne Thompson, Boyoung Kim, Richard C.A. Isaacs, H. Marie Loughran, Dai-Shi Su, John Lim, Mark W. Embrey, Peter D. Williams
  • Publication number: 20100056516
    Abstract: 1-Hydroxy naphthyridine compounds (e.g., 1-hydroxy naphthyridin-2(1H)-one compounds of Formula I are inhibitors of HIV integrase and/or HIV RNase H and inhibitors of HIV replication: (I) wherein X and R1-R6 are as defined herein. The compounds are useful in the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other anti-HIV agents such as HIV antivirals, immunomodulators, antibiotics and vaccines.
    Type: Application
    Filed: July 13, 2007
    Publication date: March 4, 2010
    Inventors: Peter D. Williams, Shankar Venkatraman, H. Marie Langford, Boyoung Kim, Theresa M. Booth, Jay A. Grobler, Donnette Staas, Rowena D. Ruzek, Mark W. Embrey, Catherine M. Wiscount, Terry A. Lyle
  • Patent number: 7538112
    Abstract: Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: May 26, 2009
    Assignee: Merck & Co., Inc.
    Inventors: John S. Wai, Joseph P. Vacca, Linghang Zhuang, Boyoung Kim, Terry A. Lyle, Catherine M. Wiscount, Melissa S. Egbertson, Lou Anne Neilson, Mark Embrey, Thorsten E. Fisher, Donnette D. Staas
  • Patent number: 7517532
    Abstract: 8,9-Dihydroxydihydropyridopyrazine-1,6-diones and 8,9-dihydroxypyridopyrazine-1,6-diones are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the pyridopyrazinediones are of Formula (I): (I), wherein R1, R2, R3, R4 and R5 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are described.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: April 14, 2009
    Assignee: Merck & Co., Inc.
    Inventors: John S. Wai, Boyoung Kim, Thorsten E. Fisher, Peter D. Williams, H. Marie Langford
  • Publication number: 20080287394
    Abstract: Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: May 3, 2005
    Publication date: November 20, 2008
    Applicant: MERCK & CO., INC.
    Inventors: John S. Wai, Joseph P. Vacca, Linghang Zhuang, Boyoung Kim, Terry A. Lyle, Catherine M. Wiscount, Melissa S. Egbertson, Lou Anne Neilson, Mark Embrey, Thorsten E. Fisher, Donnette D. Staas